A pharmaco-metabolomics approach in a clinical trial of ALS: Identification of predictive markers of progression

PLoS ONE

Volumn 13, Issue 6, 2018, Pages

  Blasco, Hélène ^a,b   Patin, Franck ^a,b   Descat, Amandine ^c   Garçon, Guillaume ^d   Corcia, Philippe ^a,e   Gelé, Patrick ^f   Lenglet, Timothée ^g   Bede, Peter ^h,i   Meininger, Vincent ^j   Devos, David ^c   Gossens, Jean François ^c   Pradat, Pierre François ^g,h,k  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIV LILLE   (France)

^d France Institut Pasteur de Lille   (France)

^e CHU BRETONNEAU   (France)

^f University of Lille   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SORBONNE UNIVERSITÉ   (France)

ⁱ TRINITY COLLEGE DUBLIN   (Ireland)

^j Hopital des Peupliers   (France)

^k UNIVERSITY OF ULSTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; CITRULLINE; GLYCINE; KYNURENINE; LIPID; OLESOXIME; PLACEBO; RILUZOLE; SPERMIDINE; SPHINGOMYELIN; CHOLEST 4 EN 3 ONE; PHARMACOLOGICAL BIOMARKER;

ADULT; AMINO ACID BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLOOD SAMPLING; CLINICAL OUTCOME; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID BLOOD LEVEL; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PREDICTION; PREDICTIVE VALUE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; AGED; CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; METABOLOME; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROGNOSIS;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS, PHARMACOLOGICAL; CHOLESTENONES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HUMANS; MALE; METABOLOME; METABOLOMICS; MIDDLE AGED; PLACEBOS; PROGNOSIS;

EID: 85048137512     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0198116     Document Type: Article

References (29)

1. Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014; 13(11):1127–38. Epub 2014/10/16. doi: S1474-4422(14)70129-2 [pii] https://doi.org/10.1016/S1474-4422(14)70129-2 PMID: 25316019.
2. Beghi E, Pupillo E, Bonito V, Buzzi P, Caponnetto C, Chio A, et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14 (5–6):397–405. Epub 2013/02/21. https://doi.org/10.3109/21678421.2013.764568 PMID: 23421600.
3. Bozik ME, Mitsumoto H, Brooks BR, Rudnicki SA, Moore DH, Zhang B, et al. A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014; 15(5–6):406–13. Epub 2014/08/16. https://doi.org/10.3109/21678421.2014.943672 PMID: 25125035.
4. Bordet T, Berna P, Abitbol JL, Pruss RM. Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals (Basel). 2010; 3(2):345–68. https://doi.org/10.3390/ ph3020345 PMID: 27713255.
5. Martin LJ. Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs. 2010; 13(8):568–80. PMID: 20721828; PubMed Central PMCID: PMC3058503.
6. Lenglet T, Lacomblez L, Abitbol JL, Ludolph A, Mora JS, Robberecht W, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur J Neurol. 2014; 21(3):529–36. https://doi.org/10.1111/ene.12344 PMID: 24447620.
7. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000; 1(5):293–9. Epub 2001/07/24. PMID: 11464847.
8. Rafiq MK, Lee E, Bradburn M, McDermott CJ, Shaw PJ. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015; 16(7–8):478–84. https://doi.org/10.3109/21678421.2015. 1062517 PMID: 26161993.
9. Patin F, Corcia P, Vourc’h P, Nadal-Desbarats L, Baranek T, Goossens JF, et al. Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism. Mol Neurobiol. 2016. https://doi.org/10.1007/s12035-016-0078-x PMID: 27590138.
10. Rinaudo P, Boudah S, Junot C, Thevenot EA. biosigner: A New Method for the Discovery of Significant Molecular Signatures from Omics Data. Front Mol Biosci. 2016; 3:26. https://doi.org/10.3389/fmolb.2016.00026 PMID: 27446929; PubMed Central PMCID: PMCPMC4914951.
11. Blasco H, Mavel S, Corcia P, Gordon PH. The glutamate hypothesis in ALS: pathophysiology and drug development. Curr Med Chem. 2014; 21(31):3551–75. Epub 2014/09/24. doi: CMC-EPUB-62359 [pii]. PMID: 25245510.
12. Blasco H, Patin F, Madji Hounoum B, Gordon PH, Vourc’h P, Andres CR, et al. Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol. 2016; 23(3):447–54. https://doi.org/10.1111/ene.12956 PMID: 26822316.
13. Paul P, de Belleroche J. The role of D-serine and glycine as co-agonists of NMDA receptors in motor neuron degeneration and amyotrophic lateral sclerosis (ALS). Front Synaptic Neurosci. 2014; 6:10. https://doi.org/10.3389/fnsyn.2014.00010 PMID: 24795623; PubMed Central PMCID: PMCPMC3997022.
14. Raiteri L, Raiteri M, Bonanno G. Coexistence and function of different neurotransmitter transporters in the plasma membrane of CNS neurons. Prog Neurobiol. 2002; 68(4):287–309. PMID: 12498989.
15. Carri MT, D’Ambrosi N, Cozzolino M. Pathways to mitochondrial dysfunction in ALS pathogenesis. Bio-chem Biophys Res Commun. 2016. https://doi.org/10.1016/j.bbrc.2016.07.055 PMID: 27416757.
16. Dai Z, Wu Z, Yang Y, Wang J, Satterfield MC, Meininger CJ, et al. Nitric oxide and energy metabolism in mammals. Biofactors. 2013; 39(4):383–91. Epub 2013/04/05. https://doi.org/10.1002/biof.1099PMID: 23553707.
17. Storch A, Burkhardt K, Ludolph AC, Schwarz J. Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem. 2000; 75(6):2259–69. PMID: 11080177.
18. Blasco H, Nadal-Desbarats L, Pradat PF, Gordon PH, Madji Hounoum B, Patin F, et al. Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. Eur J Neurol. 2016; 23(2):346–53. https://doi.org/10.1111/ene.12851 PMID: 26508442.
19. Dentel C, Palamiuc L, Henriques A, Lannes B, Spreux-Varoquaux O, Gutknecht L, et al. Degeneration of serotonergic neurons in amyotrophic lateral sclerosis: a link to spasticity. Brain. 2012. Epub 2012/11/ 02. doi: aws274 [pii] https://doi.org/10.1093/brain/aws274 PMID: 23114367.
20. Chen Y, Meininger V, Guillemin GJ. Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. Cent Nerv Syst Agents Med Chem. 2009; 9(1):32–9. PMID: 20021336.
21. Chen Y, Stankovic R, Cullen KM, Meininger V, Garner B, Coggan S, et al. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010; 18(2):132–42. Epub 2009/11/19. https://doi.org/10.1007/s12640-009-9129-7 PMID: 19921535.
22. Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996; 47(6 Suppl 4): S233–41. PMID: 8959995.
23. Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010; 17(18):1942–199. Epub 2010/04/10. doi: BSP/CMC/E-Pub/ 117 [pii]. PMID: 20377511.
24. Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014; 71(9):1134–42. https://doi.org/10.1001/jamaneurol.2014.1129 PMID: 25048026.
25. Patin F, Corcia P, Madji Hounoum B, Veyrat-Durebex C, Respaud E, Piver E, et al. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol. 2015; 22(10):1385–90. https://doi.org/10.1111/ene.12754 PMID: 26095828.
26. Henriques A, Croixmarie V, Priestman DA, Rosenbohm A, Dirrig-Grosch S, D’Ambra E, et al. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase. Hum Mol Genet. 2015; 24(25):7390–405. https://doi.org/10.1093/hmg/ddv439 PMID: 26483191; PubMed Central PMCID: PMCPMC4664174.
27. Ariga T, Jarvis WD, Yu RK. Role of sphingolipid-mediated cell death in neurodegenerative diseases. J Lipid Res. 1998; 39(1):1–16. PMID: 9469581.
28. Dodge JC, Treleaven CM, Pacheco J, Cooper S, Bao C, Abraham M, et al. Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2015; 112 (26):8100–5. https://doi.org/10.1073/pnas.1508767112 PMID: 26056266; PubMed Central PMCID: PMCPMC4491749.
29. Zhao YY, Miao H, Cheng XL, Wei F. Lipidomics: Novel insight into the biochemical mechanism of lipid metabolism and dysregulation-associated disease. Chem Biol Interact. 2015; 240:220–38. https://doi.org/10.1016/j.cbi.2015.09.005 PMID: 26358168.